Information Provided By:
Fly News Breaks for May 14, 2018
May 14, 2018 | 06:01 EDT
Piper Jaffray analyst JP McKim upgraded Tandem Diabetes to Overweight from Neutral after being on the road with the company's management. In a research note to investors, McKim said he believes Tandem is about to enter a "Goldilocks Period" where they have a "superior" closed loop system for several years. Additionally, the analyst sees upside to pump shipment with further room for multiple expansions and believes this is "just the beginning" of share appreciation. McKim has a $13 price target on the shares.
News For TNDM From the Last 2 Days
Nov 21, 2018 | 12:15 EDT
Stocks opened in positive territory and have drifted higher during the early part of the session. The day’s host... To see the rest of the story go to See Story Here
Nov 21, 2018 | 10:09 EDT
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Best Buy (BBY) upgraded to Neutral from Underperform at Wedbush with analyst Michael Pachter saying it has consistently defied his expectations and the company appears to have settled on the right formula for long-term growth. 2. (WIX) upgraded to Outperform from Sector Perform at RBC Capital with analyst Mark Mahaney citing valuation. 3. RealPage (RP) upgraded to Outperform from Sector Perform at RBC Capital with analyst Matthew Hedberg saying the company recorded one of its better quarters in years and also cites his recent positive takeaways from discussions with its management. 4. Tandem Diabetes (TNDM) upgraded to Outperform from Neutral at Baird with analyst Jeff Johnson saying he believes the recent selloff in the shares is overdone, especially in the context of Street estimates that now appear too low for 2019-2020. 5. Edison International (EIX) upgraded to Buy from Neutral at Mizuho with analyst Paul Fremont citing an analysis of the company's 2017-2018 wildfire/mudslide liabilities, the analyst estimates "more upside opportunity than downside opportunity" from current stock levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.